Korro Bio, Inc.(KRRO)

$13.14—

Chart

Korro Bio, Inc.(KRRO)

NASDAQ

$13.14—

Chart Studio

KRRO(KRRO)

KRRO

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-1.34

Aug 11, 2026 · Reports before open

Revenue Estimate

$214,286

Analyst Sentiment

Wall St. Consensus

Buy

11 analysts·Moderate coverage

Score

10 Buy (91%)1 Hold (9%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1091%

Hold

19%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$10.00

-23.9%

Consensus

$22.00

+67.4%

Bull

$30.00

+128.3%

12-Month Target Range11 analysts

$10.00$22.00$30.00

Current $13.14Consensus

Current Price

$13.14

Upside to Consensus

$8.86

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-61.90%

EPS—

FY2028

Rev+530.00%

EPS—

FY2029

Rev+1097.19%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$562,500	$214,286	$1M	$16M	$44M
Low	$562,500	$214,286	$1M	$16M	$44M
High	$562,500	$214,286	$1M	$16M	$44M
EBITDA Avg	$-112,499	$-42,857	$-269,999	$-3M	$-9M
Low	$-112,499	$-42,857	$-269,999	$-3M	$-9M
High	$-112,499	$-42,857	$-269,999	$-3M	$-9M
EBIT Avg	$-112,499	$-42,857	$-269,999	$-3M	$-9M
Low	$-112,499	$-42,857	$-269,999	$-3M	$-9M
High	$-112,499	$-42,857	$-269,999	$-3M	$-9M
Net Income Avg	$-49M	$-46M	$-51M	$-54M	$-53M
Low	$-65M	$-62M	$-73M	$-54M	$-53M
High	$-33M	$-30M	$-28M	$-54M	$-53M
EPS Avg	$-5.42	$-5.39	$-5.25	$-5.80	$-5.60
Low	$-6.89	$-6.57	$-7.81	$-5.80	$-5.60
High	$-3.51	$-3.19	$-2.94	$-5.80	$-5.60
Analysts (Rev / EPS)	7 / 9	6 / 8	7 / 8	3 / 6	6 / 6

Quarterly

Metric	Q2 2026	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$214,286	$214,286	$214,286	$500,000	—	—	—
Low	$214,286	$214,286	$214,286	$500,000	—	—	—
High	$214,286	$214,286	$214,286	$500,000	—	—	—
EBITDA Avg	$-42,857	$-42,857	$-42,857	$-99,999	—	—	—
Low	$-42,857	$-42,857	$-42,857	$-99,999	—	—	—
High	$-42,857	$-42,857	$-42,857	$-99,999	—	—	—
EBIT Avg	$-42,857	$-42,857	$-42,857	$-99,999	—	—	—
Low	$-42,857	$-42,857	$-42,857	$-99,999	—	—	—
High	$-42,857	$-42,857	$-42,857	$-99,999	—	—	—
Net Income Avg	$-16M	$-15M	$-15M	$-16M	$-17M	$-17M	$-17M
Low	$-21M	$-19M	$-15M	$-16M	$-17M	$-17M	$-17M
High	$-7M	$-7M	$-15M	$-16M	$-17M	$-17M	$-17M
EPS Avg	$-1.34	$-1.29	$-1.32	$-1.41	$-1.44	$-1.47	$-1.50
Low	$-1.82	$-1.62	$-1.32	$-1.41	$-1.44	$-1.47	$-1.50
High	$-0.57	$-0.61	$-1.32	$-1.41	$-1.44	$-1.47	$-1.50
Analysts (Rev / EPS)	5 / 7	5 / 7	2 / 3	2 / 3	— / 2	— / 2	— / 2

Earnings Surprises

Recent Analyst Actions

May 19, 2026H.C. Wainwright

Korro Bio price target lowered to $15 from $20 at H.C. Wainwright

Target:$15.00

+50.5%from $9.97

Mar 13, 2026Cantor Fitzgerald

Korro Bio (KRRO) PT Raised to $22 at Cantor Fitzgerald on UCD Potential

Target:$22.00

+91.3%from $11.50

Mar 13, 2026Raymond James

Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform

Target:$23.00

+100.0%from $11.50

Feb 18, 2026Raymond James

Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy

Target:$18.00

+60.2%from $11.23

Jan 29, 2026H.C. Wainwright

Korro Bio upgraded to Buy from Neutral at H.C. Wainwright

Target:$20.00

+71.1%from $11.69

Jan 29, 2026Chardan Capital

Korro Bio upgraded to Buy from Neutral at Chardan

Target:$15.00

+28.3%from $11.69

Jan 28, 2026Piper Sandler

Korro Bio upgraded to Overweight from Neutral at Piper Sandler

Target:$30.00

+156.6%from $11.69

Jan 28, 2026William Blair

William Blair Reiterates Market Perform Rating on Korro Bio Inc. (KRRO), 'early stages of its pipeline with clinical data unlikely until 2027'

Target:$10.00

-10.5%from $11.17

Jan 28, 2026Oppenheimer

Korro Bio upgraded to Outperform from Perform at Oppenheimer

Target:$22.00

+104.8%from $10.74

Jan 27, 2026Cantor Fitzgerald

Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald

Target:$21.00

+95.5%from $10.74

Apr 16, 2025Chardan Capital

Korro Bio initiated with a Buy at Chardan

Target:$25.00

+85.7%from $13.46

Oct 21, 2024RBC Capital

Korro Bio Inc. (KRRO) PT Raised to $105 at RBC Capital

Target:$105.00

+36.5%from $76.94

May 15, 2024BMO Capital

BMO Capital Reiterates Outperform Rating on Korro Bio Inc. (KRRO)

Target:$120.00

+139.8%from $50.05

Mar 28, 2024H.C. Wainwright

Korro Bio Inc. (KRRO) PT Raised to $115 at H.C. Wainwright, 'KRRO-110 should be well-positioned'

Target:$115.00

+29.9%from $88.53

Mar 27, 2024RBC Capital

Korro Bio Inc. (KRRO) PT Raised to $90 at RBC Capital

Target:$90.00

+0.2%from $89.83

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance